trending Market Intelligence /marketintelligence/en/news-insights/trending/f_Wrm5eunVF3fxCtxWJQeg2 content esgSubNav
In This List

Arno Therapeutics to deregister common stock

Blog

Commercial Banking: June 22nd Edition

Blog

Understanding Loss Given Default A Review of Three Approaches

Blog

Commercial Banking Newsletter June Edition - 2022

Blog

Insight Weekly: US recession outlook; mortgage activity slowdown; climate disclosure push


Arno Therapeutics to deregister common stock

The Arno Therapeutics Inc. board approved a plan to deregister the company's shares from the OTCQB.

The company plans to make a Form 15 filing with the U.S. SEC on March 30 after which the biopharmaceutical will no longer be required to file periodic and other reports.

Arno is evaluating strategic opportunities for its onapristone, AR-42 and AR-12 product candidates. Since January, the company has been taking action to reduce its expenses to conserve its cash and other resources as it evaluates potential alternatives.

Arno's decision to deregister allows it to eliminate legal, accounting and other administrative expenses that would otherwise be necessary if it remained a public reporting company.